Comparative Sensitivity of Urinary Cyfra 21-1, Urinary Bladder Cancer Antigen, Tissue Polypeptide Antigen and Nmp22    to Detect Bladder Cancer

Sänchez‐Carbayo, Marta; Herrero, Enrique; Megías, Julián; Mira, Antonio; Soria, Federico

doi:10.1016/s0022-5347(05)68076-7

Cited by 61 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 The interference of leukocytes with urine-based tests has been noted by others, 37,47,48 and excluding affected subjects is a common way of circumventing this problem. 36,37 In our series, the specificity of hTR quantification is greatly improved by excluding leukocyte contamination in urine. In its presence, bladder cancer may still be detected with sufficient specificity by applying a higher cutoff value for hTR analysis.…”

Section: Discussionmentioning

confidence: 89%

Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer

Weikert

Krause

Wolff

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of our study was to prospectively evaluate the potential diagnostic value and clinical applicability of quantitative analysis of telomerase subunits gene expression in urine for noninvasive detection of bladder cancer. Expression levels of human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR) were analyzed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in urine samples from 163 subjects with bladder cancer and 237 controls (163 individuals with benign genitourinary diseases; 74 healthy subjects). The sensitivity, specificity and optimal cutoffs were determined and compared to the corresponding values obtained by voided urine cytology. Quantitative urinary hTR analysis detects bladder cancer with an overall sensitivity of 77.0%, whereas hTERT analysis reached a sensitivity of 55.2%. The majority of undetected tumors were small, lowgrade pTa lesions. Both hTR and hTERT proved to be significantly more sensitive than cytology (34.5%; p < 0.001). Specificities for hTR, hTERT and cytology were 72.1%, 85.0% and 92.7%, respectively, in the total study population and 96.9%, 89.2% and 100%, respectively, in healthy subjects. Higher diagnostic accuracy was achieved by hTR than by hTERT analysis (p < 0.05). The specificity of hTR increased to 85.0% in the total population if urinary leukocyte contamination was excluded. These data suggest that quantitative hTR analysis is the most accurate telomerase-based test for bladder cancer detection and has the potential to replace cytology as a noninvasive biomarker for disease diagnosis and follow-up. ' 2005 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 89%

Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer

Weikert

Krause

Wolff

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Another version, called the urinary bladder cancer (UBC) test (IDL), also detects CK8 and 18. A preliminary report suggests a sensitivity of 65% and specificity of 92% for this test (276,278 ). In one method comparison study, the UBC test outperformed the BTA Stat and NMP22 tests, showing higher sensitivity and specificity for bladder cancer (279 ).…”

Section: Proposed Biomarkers Not Cleared By the Fdamentioning

confidence: 91%

“…Although the overall sensitivity is reported to be 80%, a false-positive rate of 30%-40% has limited TPA use in routine patient care (276 ). Subsequently, a tissue polypeptide-specific (TPS) test (IDL Biotech) was developed, which employs monoclonal antibodies against CK8 and 18 (277 ).…”

Section: Proposed Biomarkers Not Cleared By the Fdamentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic patients with typical hypervascular lesions >2 cm in size are consistent with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, especially in the absence of measurable disease. Although several urine markers have been proposed for bladder cancer, none at present can replace routine cystoscopy and cytology in the management of patients with this malignancy. Some may, however, be used as complementary adjuncts to direct more effective use of clinical procedures. Although carcinoembryonic antigen and CA 19-9 have been proposed for use gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.

show abstract

“…Mesane tümörlerinin %70'i ilk saptandığında yüzeyel mesane tümörüdür ve bunlar 5 yıl içeri-sinde yaklaşık %70 oranında nüks eder ve 15 yıl içerisinde bu oran %90'lara kadar yükselmektedir (4). Mesane tümörlerinin %30'u ise ilk tanı konulduğunda invaziv tümördür ve bunların yarından fazlası ise uzak metastaz yapmış durumdadır (4).…”

Section: ö öZ Ze Et Tunclassified

“…Yüzeyel mesane tümörlerinin takibinde uygulanan protokol, ilk 2 yılda 3 ayda bir, sonraki 2 yılda 6 ayda bir ve sonrasında 10 yıl sü-resince yılda bir sistoskopi ile kontrol şeklindedir (4). Sistoskopi mesane tümörlerinin tanısında >%90 sensitiviteye sahiptir (6) ancak bununla birlikte invaziv bir yöntemdir.…”

Section: ö öZ Ze Et Tunclassified

Mesane Tümörleri̇nde Tümör Beli̇rleyi̇ci̇leri̇

Şahinli¹,

Göğüş²,

Göğüş³

2003

Ankara Üniversitesi Tıp Fakültesi Mecmuası

View full text Add to dashboard Cite

Ö ÖZ ZE ET TMesane kanserleri yüksek insidansa sahip, tekrar etme eğilimi yüksek, sıkı ve düzenli takibi gereken tümörlerdir. Mesane kanserinin değerlendirilmesinde günümüzde ultrasonografi, intravenöz pyelografi ve sistoskopi sıklıkla kullanılmaktadır. Bu metodlar yüksek belirleme oranına sahip olmakla birlikte pahalı, zaman alıcı ve invaziv yön-temlerdir. Bu nedenle, yüksek sensitivite ve spesifite oranlarına sahip, noninvaziv, çabuk sonuç veren testlere gereksinim vardır. Son yıllarda mesane tümörlerinin tanı ve takibinde kullanılan çok sayıda tümör belirleyicisi mevcuttur. Bu derlemede bu tanısal testler özellikleri, uygulanışları ve doğruluk oranları açısından detaylı olarak tartışılmıştır.A An na ah ht ta ar r K Ke el li im me el le er r: : Mesane Kanseri, Tanı, İzlem, Tümör Belirleyicileri S SU UM MM MA AR RY Y T Tu um mo or r M Ma ar rk ke er rs s F Fo or r B Bl la ad dd de er r C Ca an nc ce er rs s Bladder cancers have a high incidence and high tendency to recur, necessitating close and regular follow-up. Current methods for evaluation of bladder cancers include ultrasonography, intravenous pyelography and cystoscopy. Although, these methods have a high detection rate, they are expensive, time-consuming and invasive. Therefore, there is need for noninvasive, quick diagnostic tests with a high sensitivity and specifity for the detection of bladder cancer. In last years there are an increasing number of tumor markers avaliable for the detection of bladder cancer. The specialities, applications and the detection rates of these diagnostic markers were discussed in detail in this review.K Ke ey y W Wo or rd ds s: : Bladder Cancer, Diagnosis, Follow-up, Tumor Markers Mesane kanserleri organizmanın en sık görü-len tümörlerindendir. Genel istatistiklere göre erkeklerde 4. sıklıkta görülür ve tüm kanserlerin %10'unu oluşturur. Kadınlarda ise 8. sıradadır ve kadın kanserlerinin %4'ü mesane kanserleridir. Ülkemizde sağlıklı istatistikler olmamakla birlikte dünya ortalamasının üstünde bir mesane tümörü insidansı olduğu düşünülmektedir. Genel olarak bakıldığına dünyada yılda 200.000 yeni mesane tümörlü vaka saptanmakta (1), ayrıca sadece Avrupa'da bu sayı 66.000 olarak belirlenmektedir (2). A.B.D.'de 1999 yılında yaklaşık olarak 54.000 mesane tümörü vakası tespit edilmiş olup, bunların yaklaşık olarak 12.000'i ölümle sonuçlanmıştır (3).Mesane tümörlerinin %70'i ilk saptandığında yüzeyel mesane tümörüdür ve bunlar 5 yıl içeri-sinde yaklaşık %70 oranında nüks eder ve 15 yıl içerisinde bu oran %90'lara kadar yükselmektedir (4). Mesane tümörlerinin %30'u ise ilk tanı konulduğunda invaziv tümördür ve bunların yarından fazlası ise uzak metastaz yapmış durumdadır (4).

show abstract

Comparative Sensitivity of Urinary Cyfra 21-1, Urinary Bladder Cancer Antigen, Tissue Polypeptide Antigen and Nmp22 to Detect Bladder Cancer

Cited by 61 publications

References 21 publications

Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer

Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Mesane Tümörleri̇nde Tümör Beli̇rleyi̇ci̇leri̇

Contact Info

Product

Resources

About